Jagsonpal Q1 FY27 profit rises; discloses Aequitas stake buy and buy-back

Jagsonpal Pharmaceuticals reported unaudited standalone results for the quarter ended 30 June 2026, approved by the Board on 29 July 2026. Statutory auditors Walker Chandiok & Co LLP issued a limited review report stating nothing came to their attention causing them to believe the statement contained a material misstatement.

The company operates in a single reportable segment — manufacturing and trading of pharmaceutical products, including active pharmaceutical ingredients, for customers in India and overseas.

Revenue and net profit both rose year-on-year against the June 2025 quarter, and profit was materially higher than the immediately preceding March 2026 quarter, per the filing. The specific figures appear in the key-numbers panel below.

The filing notes the March 2026 quarter figures are balancing figures derived from the audited full-year results and the reviewed nine-month figures to December 2025.

During the quarter the company undertook a buy-back of equity shares through the tender-offer route.

Separately, on 29 June 2026 it signed a Share Purchase Agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited, funded through internal accruals, with the existing promoters retaining 15% and continuing to manage the business. The filing states share transfer and closing formalities were completed subsequently in July 2026, so the transaction had no impact on the quarter's results.

The company also flags that the New Labour Codes and the Code of Wages (Central) Rules, 2026 — notified on 8 May 2026 — are being evaluated for their consequential accounting impact.

During the quarter the company granted 153,000 stock options and allotted 473,220 equity shares on exercise of vested options under its ESOP 2022, per the filing. A final dividend of ₹4 per share for the year ended 31 March 2026, recommended at the 27 April 2026 Board meeting, remains subject to shareholder approval at the AGM.